SummaryRMgm-310
|
Successful modification | The parasite was generated by the genetic modification | ||||||||||||||||
The mutant contains the following genetic modification(s) | Gene disruption, Gene disruption | ||||||||||||||||
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 19779564 | ||||||||||||||||
MR4 number | |||||||||||||||||
top of page | |||||||||||||||||
Parent parasite used to introduce the genetic modification | |||||||||||||||||
Rodent Malaria Parasite | P. berghei | ||||||||||||||||
Parent strain/line | P. berghei ANKA | ||||||||||||||||
Name parent line/clone | P. berghei ANKA 2.34 | ||||||||||||||||
Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943). | ||||||||||||||||
top of page | |||||||||||||||||
The mutant parasite was generated by | |||||||||||||||||
Name PI/Researcher | R.W. Moon; D.A. Baker; O. Billker | ||||||||||||||||
Name Group/Department | Department of Cell and Molecular Biology | ||||||||||||||||
Name Institute | Imperial College London | ||||||||||||||||
City | London | ||||||||||||||||
Country | UK | ||||||||||||||||
top of page | |||||||||||||||||
Name of the mutant parasite | |||||||||||||||||
RMgm number | RMgm-310 | ||||||||||||||||
Principal name | cdpk3 pdeδ double KO | ||||||||||||||||
Alternative name | |||||||||||||||||
Standardized name | |||||||||||||||||
Is the mutant parasite cloned after genetic modification | Yes | ||||||||||||||||
top of page | |||||||||||||||||
Phenotype | |||||||||||||||||
Asexual blood stage | Not different from wild type | ||||||||||||||||
Gametocyte/Gamete | Not different from wild type | ||||||||||||||||
Fertilization and ookinete | Normal fertilisation rates and ookinete production. Mature ookinetes showed an aberrant morphology as described for mutant ookinetes lacking expression of PDEδ (RMgm-308). The gliding motility of immature ookinetes (12-15h) was not affected as has been found in ookinetes lacking expression of only CDPK3 (RMgm-154) | ||||||||||||||||
Oocyst | Not tested | ||||||||||||||||
Sporozoite | Not tested | ||||||||||||||||
Liver stage | Not tested | ||||||||||||||||
Additional remarks phenotype | Mutant/mutation Analyses of mutants lacking expression of CDPK3 (RMgm-154, RMgm-165, RMgm-168) indicates a role for CDPK3 in regulating productive gliding motility of ookinetes. The following different genes encoding proteins with homology to cyclic nucleotide phosphodiesterase have been identified in Plasmodium
Analyses of a mutant lacking expression of PDEδ (RMgm-308) indicate that PDEδ has a crucial role in ookinete development and motility. Phenotype Disruption of the P. falciparum ortholog of PBANKA_040820 has been attempted (Solyakov et al., 2011, Nat Commun, 2:565). |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0408200 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0310100 | ||||||||||||||||||||||||
Gene product | calcium-dependent protein kinase 3 | ||||||||||||||||||||||||
Gene product: Alternative name | CDPK3 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | KpnI, BamHI | ||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption |
5' targetting region: a 608 bp fragment comprising 5′ upstream sequence followed by the first 543 bp of exon1 of cdpk3 3' targetting region: A 686 bp fragment comprising the last two exons and 3′ flanking region of pbcdpk3 No additional information on primer sequences is available. | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | No additional information on primer sequences used for the replacement construct is provided in the paper! The cdpk3 gene has been disrupted using a construct that contains the tgdhfr selectable marker and that integrates by double cross-over recombination. This mutant has been described as mutant RMgm-154. The pdeδ gene has been disrupted using a construct that contains the tgdhfr selectable marker and that integrates by double cross-over recombination. This mutant has been described as mutant RMgm-308. The cdpk3 pdeδ double KO mutant was produced by crossing (in the mosquito) the cdpk3 KO mutant and the pdeδ KO mutant. Multiple clones were genotyped to identify and select the cdpk3 pdeδ double KO mutants. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1333700 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1470500 | ||||||||||||||||||||||||
Gene product | phosphodiesterase delta, putative | ||||||||||||||||||||||||
Gene product: Alternative name | PDEδ, Phosphodiesterase delta | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | KpnI, BamHI | ||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | The cdpk3 gene has been disrupted using a construct that contains the tgdhfr selectable marker and that integrates by double cross-over recombination. This mutant has been described as mutant RMgm-154. The pdeδ gene has been disrupted using a construct that contains the tgdhfr selectable marker and that integrates by double cross-over recombination. This mutant has been described as mutant RMgm-308. The cdpk3 pdeδ double KO mutant was produced by crossing (in the mosquito) the cdpk3 KO mutant and the pdeδ KO mutant. Multiple clones were genotyped to identify and select the cdpk3 pdeδ double KO mutants. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |